Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDQOWT)

Drug Name

MOR-208 Drug Info

Synonyms

XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Phase 2/3	[1]
Autoimmune diabetes	5A10	Phase 2	[2]
B-cell chronic lymphocytic leukaemia	2A82.00	Phase 2	[3]
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[3]

Cross-matching ID

TTD Drug ID: DMDQOWT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[7]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[8]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[9]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[10]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[11]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[12]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[13]
CD19 CAR T cells	DM32148	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[4]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01685008) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin Lymphoma (NHL). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
5	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
11	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
12	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
13	ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
14	ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma